Grafalon® (Anti-lymphocyte Globulin)
Prophylaxis of Graft-versus-Host Disease (GvHD)
Key Facts
Indication
Prophylaxis of Graft-versus-Host Disease (GvHD)
Phase
Licensed
Status
Development for China
Company
About Fosun Pharma
Fosun Pharma's mission is to be the global leading integrator of pharmaceutical and healthcare innovation, delivering 'Better Health for Families Worldwide.' The company has achieved significant milestones, including China's first approved CAR-T cell therapy (Yi Kai Da), a leading biosimilar portfolio, and the WHO-recommended antimalarial Artesun®. Its strategy combines independent R&D with aggressive in-licensing and global partnerships to build a diversified portfolio across therapeutics, vaccines, and diagnostics, supported by a vast commercial network through its stake in Sinopharm.
View full company profile